title: How we treat: risk mitigation for ABO-incompatible plasma in plateletpheresis products.
authors.affiliation: Department of Pathology, Stanford Hospital and Clinics, Stanford University, Stanford, California 94305-5626, USA. magalif@stanford.edu
authors.forename: Magali J
authors.initials: MJ
authors.lastname: Fontaine
authors.forename: Anne M
authors.initials: AM
authors.lastname: Mills
authors.forename: Susan
authors.initials: S
authors.lastname: Weiss
authors.forename: Wan-Jen
authors.initials: WJ
authors.lastname: Hong
authors.forename: Maurene
authors.initials: M
authors.lastname: Viele
authors.forename: Lawrence T
authors.initials: LT
authors.lastname: Goodnough
mesh_terms: D000017:ABO Blood-Group System / Q000235:genetics / Q000276:immunology*; D058186:Acute Kidney Injury / Q000209:etiology / Q000628:therapy; D000743:Anemia, Hemolytic / Q000209:etiology* / Q000276:immunology; D001787:Blood Group Incompatibility / Q000209:etiology* / Q000276:immunology / Q000517:prevention & control; D003176:Complement C3 / Q000032:analysis; D003298:Coombs Test; D017707:Erythrocyte Transfusion; D017809:Fatal Outcome; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007074:Immunoglobulin G / Q000097:blood / Q000276:immunology; D007518:Isoantibodies / Q000097:blood / Q000276:immunology; D015470:Leukemia, Myeloid, Acute / Q000276:immunology / Q000628:therapy; D017710:Lymphocyte Transfusion; D008875:Middle Aged; D016134:Organizational Policy; D010949:Plasma / Q000276:immunology*; D017713:Platelet Transfusion / Q000009:adverse effects* / Q000379:methods / Q000592:standards; D010983:Plateletpheresis / Q000379:methods*; D011183:Postoperative Complications / Q000209:etiology* / Q000276:immunology; D006435:Renal Dialysis; D040242:Risk Reduction Behavior; D014184:Transplantation, Homologous / Q000276:immunology
chemical_list: D000017:ABO Blood-Group System; D003176:Complement C3; D007074:Immunoglobulin G; D007518:Isoantibodies